BC Extra | Apr 16, 2016
Financial News

Organogenesis raises $30M round

Wound care company Organogenesis Inc. (Canton, Mass.) said it raised about $30 million in a venture round from existing investors. Organogenesis markets Apligraf and Dermagraft to treat diabetic foot ulcers and other chronic wounds. Apligraf...
BC Week In Review | Jan 27, 2014
Clinical News

MatriStem MicroMatrix: Phase IV started

ACell began a single-blind, U.S. Phase IV trial to compare standard of care (SOC) plus MatriStem MicroMatrix particles or MatriStem Wound Matrix sheets vs. SOC plus Dermagraft in about 102 patients with diabetic foot ulcers...
BC Week In Review | Jan 20, 2014
Company News

Organogenesis, Shire deal

Organogenesis purchased wound healing product Dermagraft human fibroblast-derived dermal substitute ( ABH001 ) from Shire. Shire will not receive an upfront payment but is eligible for up to $300 million in milestones based on annual net sales...
BC Extra | Jan 18, 2014
Company News

Organogenesis acquires Shire's Dermagraft

Regenerative medicine company Organogenesis Inc. (Canton, Mass.) purchased wound healing product Dermagraft from Shire plc (LSE:SHP; NASDAQ:SHPG). Shire will not receive an upfront payment but is eligible for up to $300 million in milestones through...
BC Week In Review | Nov 11, 2013
Clinical News

Dermagraft: Development discontinued

Shire disclosed in its 3Q13 earnings that it discontinued development of ABH001 to treat epidermolysis bullosa as part of a pipeline prioritization. The product was in an open-label, international Phase III trial. Shire said the...
BioCentury | May 20, 2013

Let a thousand ideas bloom

Shire plc has long been a growth through acquisition company, but the pace of its external discovery is picking up steam and the company now has over 20 ongoing projects to show for it. Traditional...
BioCentury | May 20, 2013

R&D rewind

At first blush, new Shire plc CEO Flemming Ornskov's plan to invest in early R&D while integrating business units looks like a rehash of the company's strategy from 2000. But Ornskov expects the latest move...
BioCentury | Apr 29, 2013

Alleviating lesions

Alleviating lesions Morgenthaler believes it has finally found a good entry point into wound healing via Scioderm LLC 's $16 million series A round. The proceeds will fund a therapy to treat chronic wounds and...
BC Week In Review | Feb 18, 2013
Clinical News

Dermagraft: Phase III started

Shire began an open-label, international Phase III trial to compare topical ABH001 applied every 4 weeks plus protocol-specified dressings vs. control wound care plus protocol-specified dressings for up to 24 weeks in about 20 patients...
BC Week In Review | Jan 14, 2013
Company News

Lotus Tissue Repair, Shire deal

Shire will acquire Lotus Tissue Repair for an undisclosed upfront payment, plus milestones. Shire will gain Lotus Tissue's lead product, a preclinical recombinant form of human collagen Type VII (rC7) in development as an IV...
Items per page:
1 - 10 of 145